
Claims


1. Polymorph Form A of the compound of Formula I:



Formula I

2. Polymorph Form A of claim 1, wherein Form A is characterized by major peaks of X-ray powder diffraction pattern as shown in Figure 1.

3. A pharmaceutical composition comprising a therapeutically effective amount of the compound of Formula I



Formula I

or a pharmaceutically acceptable salt, hydrate, and/or solvate thereof, and a pharmaceutically acceptable carrier; wherein said composition comprises polymorph Form A of claim 2.

4. The pharmaceutical composition of claim 3 further comprising one or more polymorphic forms of the compound of Formula I other than polymorph Form A.

5. The pharmaceutical composition of claim 3, wherein the composition comprises more than one polymorphic forms of the compound of Formula I in hydrated or solvated form.

6. The pharmaceutical composition of claim 5, wherein the composition comprises a hydrate of Form A.

7. The pharmaceutical composition of claim 5, wherein the composition comprises solvate of Form A.

8. The pharmaceutical composition of claim 7, wherein the solvate is a dimethylacetamide solvate.

9. Use of polymorph Form A of claim 1 or 2, or use of the pharmaceutical composition of claim 3, in the preparation of a medicament for treating an mTOR associated disorder, wherein the disorder is cancer.